BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 38315407)

  • 1. Decentralized Clinical Trials: Scientific Considerations Through the Lens of the Estimand Framework.
    Izem R; Zuber E; Daizadeh N; Bretz F; Sverdlov O; Edrich P; Branson J; Degtyarev E; Sfikas N; Hemmings R
    Ther Innov Regul Sci; 2024 May; 58(3):495-504. PubMed ID: 38315407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marking 2-Years of New Thinking in Clinical Trials: The Estimand Journey.
    Fletcher C; Hefting N; Wright M; Bell J; Anzures-Cabrera J; Wright D; Lynggaard H; Schueler A
    Ther Innov Regul Sci; 2022 Jul; 56(4):637-650. PubMed ID: 35462609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of estimand framework in ICH E9 (R1) to safety evaluation.
    Wang X; Yang P; Yuan SS; Wang WWB
    J Biopharm Stat; 2023 Jul; 33(4):476-487. PubMed ID: 36951445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimand framework: Delineating what to be estimated with clinical questions of interest in clinical trials.
    Jin M; Liu G
    Contemp Clin Trials; 2020 Sep; 96():106093. PubMed ID: 32777382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating estimands into clinical trial statistical analysis plans.
    Kang M; Kendall MA; Ribaudo H; Tierney C; Zheng L; Smeaton L; Lindsey JC
    Clin Trials; 2022 Jun; 19(3):285-291. PubMed ID: 35257600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimands in hematologic oncology trials.
    Sun S; Weber HJ; Butler E; Rufibach K; Roychoudhury S
    Pharm Stat; 2021 Jul; 20(4):793-805. PubMed ID: 33686762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the Estimand Framework to Manage the Disruptive Effects of COVID-19 on Stroke Clinical Trials.
    Yassi N; Hayward KS; Campbell BCV; Churilov L
    Stroke; 2021 Nov; 52(11):3739-3747. PubMed ID: 34587797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimands and Complex Innovative Designs.
    Collignon O; Schiel A; Burman CF; Rufibach K; Posch M; Bretz F
    Clin Pharmacol Ther; 2022 Dec; 112(6):1183-1190. PubMed ID: 35253205
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implementation of ICH E9 (R1): A Few Points Learned During the COVID-19 Pandemic.
    Qu Y; Lipkovich I
    Ther Innov Regul Sci; 2021 Sep; 55(5):984-988. PubMed ID: 33983621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining estimands for efficacy assessment in single arm phase 1b or phase 2 clinical trials in oncology early development.
    Englert S; Mercier F; Pilling EA; Homer V; Habermehl C; Zimmermann S; Kan-Dobrosky N
    Pharm Stat; 2023; 22(5):921-937. PubMed ID: 37403434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Decentralized clinical trials (DCTs): A few ethical considerations.
    Petrini C; Mannelli C; Riva L; Gainotti S; Gussoni G
    Front Public Health; 2022; 10():1081150. PubMed ID: 36590004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Handling intercurrent events and missing data in non-inferiority trials using the estimand framework: A tuberculosis case study.
    Rehal S; Cro S; Phillips PP; Fielding K; Carpenter JR
    Clin Trials; 2023 Oct; 20(5):497-506. PubMed ID: 37277978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estimation of treatment effects in short-term depression studies. An evaluation based on the ICH E9(R1) estimands framework.
    Mitroiu M; Teerenstra S; Oude Rengerink K; Pétavy F; Roes KCB
    Pharm Stat; 2022 Sep; 21(5):1037-1057. PubMed ID: 35678545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective.
    Sessa C; Cortes J; Conte P; Cardoso F; Choueiri T; Dummer R; Lorusso P; Ottmann O; Ryll B; Mok T; Tempero M; Comis S; Oliva C; Peters S; Tabernero J
    ESMO Open; 2022 Feb; 7(1):100339. PubMed ID: 34953404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A narrative review of estimands in drug development and regulatory evaluation: old wine in new barrels?
    Mitroiu M; Oude Rengerink K; Teerenstra S; Pétavy F; Roes KCB
    Trials; 2020 Jul; 21(1):671. PubMed ID: 32703247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials?
    Lawrance R; Degtyarev E; Griffiths P; Trask P; Lau H; D'Alessio D; Griebsch I; Wallenstein G; Cocks K; Rufibach K
    J Patient Rep Outcomes; 2020 Aug; 4(1):68. PubMed ID: 32833083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimands in observational studies: Some considerations beyond ICH E9 (R1).
    Li H; Wang C; Chen WC; Lu N; Song C; Tiwari R; Xu Y; Yue LQ
    Pharm Stat; 2022 Sep; 21(5):835-844. PubMed ID: 35128808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opportunities and challenges with decentralized trials in Neuroscience.
    Burger HU; Van de Casteele T; Rantell KR; Corey-Lisle P; Sfikas N; Abt M;
    Biom J; 2023 Dec; 65(8):e2200370. PubMed ID: 37609878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of the Estimand Framework to Anesthesia Trials.
    De Silva AP; Leslie K; Braat S; Grobler AC
    Anesthesiology; 2024 Jul; 141(1):13-23. PubMed ID: 38743905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Estimands in published protocols of randomised trials: urgent improvement needed.
    Kahan BC; Morris TP; White IR; Carpenter J; Cro S
    Trials; 2021 Oct; 22(1):686. PubMed ID: 34627347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.